Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)

NCT06051721 is registered in ClinicalTrials.gov with Cybin IRL Limited as lead sponsor.

NCT NCT06051721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06051721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)
Lead sponsor
Cybin IRL Limited
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2024
Completion date
August 5, 2026
Enrollment
36 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder